Genetic testing for Alzheimer's disease

Medical Journal of Australia

Volumn 172, Issue 7, 2000, Pages 339-343

  Panegyres, Peter K ^a,c   Goldblatt, Jack ^b   Walpole, Ian ^b   Connor, Carmela ^a   Liebeck, Toni ^a   Harrop, Karen ^b  

^a Neurosciences Unit   (Australia)

^b KING EDWARD MEMORIAL HOSPITAL   (Australia)

^c ROYAL PERTH HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ALZHEIMER DISEASE; DEGENERATIVE DISEASE; DIAGNOSTIC TEST; FAMILY HISTORY; GENE MUTATION; GENOTYPE; HUMAN; NEUROLOGIC DISEASE; PATIENT COUNSELING; REVIEW; RISK FACTOR;

EID: 0034599585     PISSN: 0025729X     EISSN: None     Source Type: Journal    
DOI: 10.5694/j.1326-5377.2000.tb123984.x     Document Type: Review

References (35)

1. Henderson AS, Jorm AF. Dementia in Australia. Aged and Community Care Service Development and Evaluation Report No. 35. Canberra: AGPS, 1998.
2. Lehrman S. Genetic testing for Alzheimer's disease "not appropriate". Nature 1997; 389: 898.
3. Tanzi RE, Kovacs DM, Kim T-W, et al. The gene defects responsible for familial Alzheimer's disease. Neurobiol Dis 1996; 3: 159-168.
4. McKhann G, Drachman DD, Folstein M, et al. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of the Department of Health and Human Services Task Force in Alzheimer's disease. Neurology 1984; 34: 939-944.
5. World Federation of Neurology: Research Committee. Research Group on Huntington's Chorea. Ethical issues policy statement on Huntington's disease molecular genetics predictive test. J Neurol Sci 1989; 94: 327-332.
6. Went L. Ethical issues policy statement on Huntington's disease molecular genetics predictive test. International Huntington Association World Federation of Neurology. J Med Genet 1990; 27: 34-38.
7. Guidelines for the molecular genetics predictive test in Huntington's disease. International Huntington Association (IHA) and the World Federation of Neurology (WFN) Research Group on Huntington's Chorea. Neurology 1994; 44: 1533-1536.
8. Walpole I, Bankier A, Blackwell J, et al. Guidelines for DNA predictive testing. Bull Hum Genet Soc Austral 1998; 11: 10-14.
9. Goate AM, Chartier-Harlin MC, Mullan MC, et al. Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease. Nature 1991; 349: 704-706.
10. Blacker D, Tanzi RE. The genetics of Alzheimer disease. Arch Neurol 1998; 55: 294-296.
11. Levy-Lehad E, Wasco W, Podrkaj P, et al. Candidate gene for the chromosome 1 familial Alzheimer disease locus. Science 1995, 269: 973-977.
12. Saunders AM, Strittmatter WJ, Schmechel D, et al. Association of apolipoprotein E allele epsilon 4 with late-onset familial and sporadic Alzheimer's disease. Neurology 1993; 43: 1467-1472.
13. Strittmatter WJ, Saunders AM, Schmechel D, et al. Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc Natl Acad Sci USA 1993; 90: 1977-1993.
14. Gomez-Isla T, West HL, Rebeck GW, et al. Clinical and pathological correlates of apolipoprotein E ε4 in Alzheimer's disease. Ann Neurol 1996; 39: 62-70.
15. Jonker C, Schmand B, Lindeboom J, et al. Association between apolipoprotein E ε4 and the rate of cognitive decline in community-dwelling elderly individuals with and without dementia. Arch Neurol 1998; 55: 1065-1069.
16. Hyman BT, Gomez-Isla T, Briggs M, et al. Apolipoprotein E and cognitive change in an elderly population. Ann Neurol 1996; 40: 55-66.
17. Mayeux R, Saunders AM, Shea S, et al. Utility of the apolipoprotein E genotype in the diagnosis of Alzheimer's disease. N Engl J Med 1998; 338: 506-511.
18. McConnell LM, Sanders GD, Owens DK. Evaluation of genetic tests: APOE genotyping for the diagnosis of Alzheimer's disease. Genet Test 1999; 3: 47-53.
19. American College of Medical Genetics and American Society of Human Genetics Working Group on APOE and Alzheimer Disease. Statement on use of apolipoprotein E testing for Alzheimer disease JAMA 1995; 274: 1627-1629.
20. McConnell LM, Koenig BA, Greely HT, Raffin TA, and Alzheimer Disease Working Group of the Stanford Programme in Genomics, Ethics and Society. Genetic testing and Alzheimer disease: Has the tine come? Nature Medicine 1998; 4: 757-759.
21. National Institute on Aging and Alzheimer's Association Working Group. Apolipoprotein E genotyping in Alzheimer's disease. Lancet 1996; 347: 1091-1095.
22. Post SG, Whitehouse PJ, Binstock RH, et al. The clinical introduction of genetic testing for Alzheimer disease. JAMA 1997; 277: 832-836.
23. Relkin NR, Kwon YJ, Tsai J Gandy S. The National Institute on Aging/ Alzheimer's Association recommendations on the application of apolipoprotein E genotyping to Alzheimer's disease. Ann NY Acad Sci 1996; 802: 149-171.
24. Jobst KA, Hindley NJ, King E, Smith AD. The diagnosis of Alzheimer's disease: a question of image? J Clin Psychiatry 1994; 55 Suppl: S22-S31.
25. Spinnler H, Della Sala S. The role of clinical neuropsychology in the neurological diagnosis of Alzheimer's disease. J Neurol 1988; 235: 258-271.
26. Zakzanis KK. Quantitative evidence for neuroanatomic and neuropsychological markers in dementia of the Alzheimer's type. J Clin Exp Neuropsychol 1998; 20: 259-269.
27. Bullido MJ, Artiga MJ, Recuero M, et al. A polymorphism in the regulatory region of APOE associated with risk for Alzheimer's dementia. Nat Genet 1998; 18: 69-71.
28. Blacker D, Wilcox MA, Laird NM, et al. Alpha-2 macroglobulin is genetically associated with Alzheimer disease. Nat Genet 1998; 19: 357-360.
29. Kang DE, Saitoh T, Chen X, et al. Genetic association of the low density lipoprotein receptor-related protein gene (LRP), an apolipoprotein E receptor, with late-onset Alzheimer's disease. Neurology 1997; 49: 56-61.
30. Montoya SE, Aston CE, Dekosky ST, et al. Bleomycin hydrolase is associated with risk of sporadic Alzheimer's disease. Nat Genet 1998; 18: 211-212.
31. Lehmann DJ, Johnston C and Smith AD. Synergy between the genes for butyrylcholinesterase K variant and apolipoprotein E4 in late onset confirmed Alzheimer's disease. Hum Mol Genet 1997; 11: 1933-1936.
32. Panegyres PK, Mamotte CDS, Vasikaran SD, et al. Butyrylcholinesterase K variant and Alzheimer's disease. J Neurol 1999; 246: 369-370.
33. Payami H, Schellenberg GD, Zareparsi S, et al. Evidence for association of HLA-A2 allele with onset age of Alzheimer's disease. Neurology 1997; 49: 512-518.
34. Almqvist EW, Bloch M, Brinkman R, et al. On behalf of an international Huntington disease collaborative group. A worldwide assessment of the frequency of suicide, suicide attempts, or psychiatric hospitalization after predictive testing for Huntington's disease. Am J Hum Genet 1999; 64: 1293-1304.
35. Taylor SD. Demand for predictive genetic testing for Huntington's disease in Australia, 1987 to 1993. Med J Aust 1994; 161: 351-354.